As we know, EGFR T790M mutation was an independent predictor of decreased progression-free survival (PFS) in patients with NSCLC who received TKI treatment [23], pre-existing EGFR T790M clones may induce early EGFR T790M-acquired resistance [24]. Here, EGFR is linked to non-small cell lung carcinoma.